SEARCH:   Advanced

Blood, 15 May 2004, Vol. 103, No. 10, pp. 3644-3654. Prepublished online as a Blood First Edition Paper on January 15, 2004; DOI 10.1182/blood-2003-06-2071. This Article Full Text (PDF) All Versions of this Article: 2003-06-2071v1 103/10/3644    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kindler, T. Articles by Fischer, T. Search for Related Content PubMed PubMed Citation Articles by Kindler, T. Articles by Fischer, T. Related Collections Related Letter in Blood Online Social Bookmarking                   What's this? Submitted June 26, 2003 Accepted December 4, 2003 The efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Joachim Beck, Georg Hess, Birgit Weinkauf, Justus Duyster, Christian Peschel, Charles J Kirkpatrick, Matthias Theobald, Harald Gschaidmeier, Christoph Huber, and Thomas Fischer* Department of Hematology/Oncology, Johannes Gutenberg-University, Mainz, Germany Department of Pathology, Johannes Gutenberg-University, Mainz, Germany Novartis Pharma AG, Nuernberg, Germany III.Medical Department, Technical University Munich, Munich, Germany * Corresponding author; email: t.fischer{at}3-med.klinik.uni-mainz.de. This phase II pilot study was conducted to determine the efficacy and safety of imatinib mesylate in patients with c-kit positive AML refractory to or not eligible for chemotherapy. Twenty-one patients were enrolled and received imatinib 600 mg orally once daily. Five responses were seen primarily in patients starting with relatively low blast counts in bone marrow (BM) and peripheral blood (PB): two patients who were considered refractory upon chemotherapy based on persistence of blasts in PB and BM met the criteria for complete hematologic remission, one patient had no evidence of leukemia and two patients achieved a minor response. Treatment with imatinib demonstrated a good safety profile and was well tolerated. Western blot analysis and immunohistochemistry demonstrated c-Kit activation in primary AML cells. Further, imatinib treatment of primary AML cells inhibited c-Kit tyrosine-phosphorylation. Genomic DNA-sequencing of c-KIT showed no mutations in exons 2,8,10,11,12, and 17. Although some of the responses derived from relatively small reductions in leukemic blasts and may be attributable, in part, to prior chemotherapy, these cases suggest that imatinib has interesting clinical activity in a subset of c-kit positive AML patients. Further clinical trials are warranted to explore the clinical potential of imatinib in AML and to identify the underlying molecular mechanism. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Imatinib mesylate in the treatment of c-kit–positive acute myeloid leukemia: is this the real target? Michele Malagola, Giovanni Martinelli, Michela Rondoni, Stefania Paolini, Stavrula Gaitani, Mario Arpinati, Pier Paolo Piccaluga, Marilina Amabile, Constanza Basi, Emanuela Ottaviani, Anna Candoni, Enrico Gottardi, Daniela Cilloni, Monica Bocchia, Giuseppe Saglio, Francesco Lauria, Renato Fanin, Giuseppe Visani, Maria Carla Marrè, Michela Maderna, Francesca Rancati, Vincenza Vinaccia, Domenico Russo, Michele Baccarani, Thomas Kindler, Florian Heidel, and Thomas Fischer Blood 2005 105: 904-905. [Full Text] [PDF] This article has been cited by other articles: F. Breitenbuecher, S. Schnittger, R. Grundler, B. Markova, B. Carius, A. Brecht, J. Duyster, T. Haferlach, C. Huber, and T. Fischer Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor Blood, April 23, 2009; 113(17): 4074 - 4077. [Abstract] [Full Text] [PDF] F. Breitenbuecher, B. Markova, S. Kasper, B. Carius, T. Stauder, F. D. Bohmer, K. Masson, L. Ronnstrand, C. Huber, T. Kindler, et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML Blood, April 23, 2009; 113(17): 4063 - 4073. [Abstract] [Full Text] [PDF] Z.-B. Han, H. Ren, H. Zhao, Y. Chi, K. Chen, B. Zhou, Y.-j. Liu, L. Zhang, B. Xu, B. Liu, et al. Hypoxia-inducible factor (HIF)-1{alpha} directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF) Carcinogenesis, October 1, 2008; 29(10): 1853 - 1861. [Abstract] [Full Text] [PDF] D. B. Lipka, L. S. Hoffmann, F. Heidel, B. Markova, M.-C. Blum, F. Breitenbuecher, S. Kasper, T. Kindler, R. L. Levine, C. Huber, et al. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells Mol. Cancer Ther., May 1, 2008; 7(5): 1176 - 1184. [Abstract] [Full Text] [PDF] T. Haferlach Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia Hematology, January 1, 2008; 2008(1): 400 - 411. [Abstract] [Full Text] [PDF] K. J Randall and J. R. Foster The Demonstration of Immunohistochemical Biomarkers in Methyl Methacrylate-Embedded Plucked Human Hair Follicles Toxicol Pathol, December 1, 2007; 35(7): 952 - 957. [Abstract] [Full Text] [PDF] P. P. Piccaluga, M. Malagola, M. Rondoni, M. Arpinati, S. Paolini, A. Candoni, R. Fanin, E. Messa, M. T. Pirrotta, F. Lauria, et al. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. Haematologica, December 1, 2007; 92(12): 1721 - 1722. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] K. K. Eklund, A. Remitz, H. Kautiainen, S. Reitamo, and M. Leirisalo-Repo Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients Rheumatology, December 1, 2006; 45(12): 1573 - 1575. [Full Text] [PDF] F. Heidel, F. K. Solem, F. Breitenbuecher, D. B. Lipka, S. Kasper, M. H. Thiede, C. Brandts, H. Serve, J. Roesel, F. Giles, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain Blood, January 1, 2006; 107(1): 293 - 300. [Abstract] [Full Text] [PDF] J. Cammenga, S. Horn, U. Bergholz, G. Sommer, P. Besmer, W. Fiedler, and C. Stocking Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate Blood, December 1, 2005; 106(12): 3958 - 3961. [Abstract] [Full Text] [PDF] S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF] D. S. Krause and R. A. Van Etten Tyrosine Kinases as Targets for Cancer Therapy N. Engl. J. Med., July 14, 2005; 353(2): 172 - 187. [Full Text] [PDF] Y.-Y. Wang, G.-B. Zhou, T. Yin, B. Chen, J.-Y. Shi, W.-X. Liang, X.-L. Jin, J.-H. You, G. Yang, Z.-X. Shen, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec PNAS, January 25, 2005; 102(4): 1104 - 1109. [Abstract] [Full Text] [PDF] M. Malagola, G. Martinelli, M. Rondoni, S. Paolini, S. Gaitani, M. Arpinati, P. P. Piccaluga, M. Amabile, C. Basi, E. Ottaviani, et al. Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? Blood, January 15, 2005; 105(2): 904 - 905. [Full Text] [PDF] H. Sihto, M. Sarlomo-Rikala, O. Tynninen, M. Tanner, L. C. Andersson, K. Franssila, N. N. Nupponen, and H. Joensuu KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors J. Clin. Oncol., January 1, 2005; 23(1): 49 - 57. [Abstract] [Full Text] [PDF] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF] M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF] T. Kindler, F. Breitenbuecher, S. Kasper, E. Estey, F. Giles, E. Feldman, G. Ehninger, G. Schiller, V. Klimek, S. D. Nimer, et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML) Blood, January 1, 2005; 105(1): 335 - 340. [Abstract] [Full Text] [PDF] A. Pardanani and A. Tefferi Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders Blood, October 1, 2004; 104(7): 1931 - 1939. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020